References
- Johnson D. Pharmacology and safety of phenyl-propanolamine. Drug Development Research 1991; 22: 197 —207.
- Aschan G. Decongestion of nasal mucous membranes by oral medication in acute rhinitis. Acta Otolaryngol 1974; 77: 433–8.
- Broms P, Malm L. Oral vasoconstrictors in perennial non-allergic rhinitis. Allergy 1982; 37: 67–74.
- Anggard A, Malm L. Orally administered decongestant drugs in disorders of the upper respiratory passages: a survey of clinical results. Clin Otolaryngol 1983; 9: 43–9.
- Horowitz J, Howes LG, Christophidis N, et al. Hyper-tensive responses induced by phenylpropanolamine in anoretic and decongestant preparations. Lancet 1980; 1: 60–1.
- Glidden R, Dibona F. Urinary retention associated with ephedrine. J Pediatr 1977; 90: 1013–4.
- Juto J, Lundberg C. An optical method for determin-ing nasal mucosal congestion in man. Acta Otolaryngol (Stockh) 1982; 94: 149–56.
- Hilberg O, Jackson AC, Swift DL, Pedersen OF. Acoustic rhinometry; evaluation of nasal cavity geome-try by acoustic reflection. J Appl Physiol 1989; 66: 295–303.
- Hallén H, Enerdal J, Graf P. Fluticasone propionate nasal spray is more effective and has a faster onset of action than placebo in treatment of rhinitis medica-mentosa. Clin Exp Allergy 1997; 27: 552–8.
- Renvall U, Lindqvist A. A double-blind clinical study with monydrin tablets in patients with non-allergic chronic rhinitis. J Int Med Res 1979; 7: 235–9.
- Grönborg H, Winther B, Brofeldt S, Borum P, Mygind N. Effects of oral norephedrine on common cold symp-toms. Rhinology 1983; 21: 3–12.
- Melén I, Andersson L, Ivarsson A, Jannert M, Jo-hansson CJ. Effects of phenylpropanolamine on ostial and nasal airway resistance in healthy individuals. Acta Otolaryngol (Stockh) 1986; 102: 99–105.
- Akerlund A, Klint T, Olén L, Rundcrantz H. Nasal decongestant effect of oxymetazoline in the common cold: an objective dose-response study in 106 patients. J Laryngol Otol 1989; 103: 743–6.
- Graf P. Overuse of oxy- and xylometazoline nasal sprays. Changes in nasal mucosal swelling and his tamine sensitivity in healthy subjects and in patients with rhinitis medicamentosa. Thesis, Karolinska Insti-tute, 1994.
- Stockley C, Wing L, Tonkin A, Miners J. Dispositional factors do not contribute to the enantiospecificity of the cardiovascular effects of phenylpropanolamine. Clin Pharmacol Ther 1994; 55: 35–43.
- Moya-Huff F, Kiritsy P, Maher T. Cardiovascular differences between phenylpropanolamine and its re-lated norephedrine isomers in the rat. J Pharm Sci 1987; 76: 114–6.
- Lake CR, Chernow B, Zaloga G, Labow J, Quirk RS, Hedges SM. The effect of phenylpropanolamine on human sympathetic nervous system function. Neu-ropsychopharmacology 1988; 1: 163–8.
- Lake CR, Gallant S, Masson E, Miller P. Adverse drug effects attributed to phenylpropanolamine: A review of 142 case reports. Am J Med 1990; 89: 195–208.